1831P Role of body composition (bc) in advanced non-small cell lung cancer (NSCLC) patients receiving first-line pembrolizumab (pembro)

Pilotto, Sara; Trestini, Ilaria; Sperduti, Isabella; Sposito, Marco; Kadrija, D.; Dodi, Alessandra; Cintoni, Marco; Drudi, A.; Aluffi, Gregorio; Belluomini, Lorenzo; Sartori, Giulia; Casali, M.; Lombardo, Francesca; Tregnago, Daniela; Avancini, Alice; Carbognin, Luisa; D’Onofrio, Mirko; Mele, M.C.; Bria, Emilio; Milella, Michèle

doi:10.1016/j.annonc.2020.08.1478

Annals of Oncology

2020

DOI: 10.1016/j.annonc.2020.08.1478

|View full text |Cite

1831P Role of body composition (bc) in advanced non-small cell lung cancer (NSCLC) patients receiving first-line pembrolizumab (pembro)

Sara Pilotto

Ilaria Trestini

Isabella Sperduti

et al.

Abstract: chemotherapy. FFMI measured by BIA is a useful tool to detect patient-at-risk in this situation, so preventive measures could be considered to improve treatment outcomes.Clinical trial identification: TCTR20190702004.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

334 Leonard St

Brooklyn, NY 11211

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

1831P Role of body composition (bc) in advanced non-small cell lung cancer (NSCLC) patients receiving first-line pembrolizumab (pembro)

Abstract: chemotherapy. FFMI measured by BIA is a useful tool to detect patient-at-risk in this situation, so preventive measures could be considered to improve treatment outcomes.Clinical trial identification: TCTR20190702004.

This publication either has no citations yet, or we are still processing them

See others like this or search for similar articles

Contact Info

Product

Resources

About